Paige Britt is an assistant editor for Targeted Oncology covering gyencologic cancers and lyphomas. Contact her at pbritt@targetedonc.com.
Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.
A recent trial shows omacetaxine and venetoclax combination benefits patients with MDS but not AML, highlighting the need for further research.
Nirogacestat shows significant long-term benefits in treating desmoid tumors, improving survival rates and patient outcomes with manageable side effects.
The COMPETE trial reveals ITM-11 significantly improves progression-free and overall survival in patients with gastroenteropancreatic neuroendocrine tumors.
Zenocutuzumab gains FDA breakthrough therapy designation for advanced cholangiocarcinoma, showcasing promising trial results and potential targeted treatment options.
A clinical trial reveals no survival benefit from stem cell transplantation in lower-risk MDS patients, highlighting the need for improved posttransplant outcomes.
The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes and improving patient outcomes.
A phase 1 trial reveals camu camu's safety and potential benefits in melanoma and NSCLC patients undergoing immune checkpoint therapy.
Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.
A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.
Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.
New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.
Expert Joe DePinto analyzes the 2025 Cell and Gene Therapy Report, highlighting industry barriers and the growing role of oncologists in patient access.
Sunvozertinib shows promising efficacy and safety in treating advanced NSCLC with EGFR exon 20 mutations, paving the way for future research.
The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.
Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.
A new study shows mRNA-4359 combined with pembrolizumab offers promising results for melanoma patients resistant to prior therapies.
Tagraxofusp shows manageable safety but limited efficacy in chronic myelomonocytic leukemia (CMML), with ongoing studies exploring combination therapies for better outcomes.
Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a pivotal phase 3 trial.
Xevinapant fails to enhance event-free survival (EFS) in head and neck cancer patients, revealing safety concerns and detrimental effects in treatment outcomes.
New dosimetry data highlights the safety and efficacy of ITM-11 for treating patients with gastroenteropancreatic neuroendocrine tumors, promising improved outcomes.
Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.
A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.
A phase 2 trial reveals that ONO-4578 and nivolumab significantly extend progression-free survival in advanced gastric cancer patients.
A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.
A recent study reveals that systematic mediastinal lymph node dissection is unnecessary for stage T1 GGO-dominant lung adenocarcinoma, enhancing patient outcomes.
A new study reveals casdatifan's promising efficacy in treating late-stage kidney cancer, showing significant progression-free survival and response rates.
Ziftomenib shows promising results in treating relapsed/refractory acute myeloid leukemia with NPM1 mutations, offering hope for improved patient outcomes.
FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.